Bortezomib, cyclophosphamide, dexamethasone versus lenalidomide, cyclophosphamide, dexamethasone in multiple myeloma patients at first relapse.
bortezomib
lenalidomide
myeloma
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
03 2020
03 2020
Historique:
received:
04
07
2019
accepted:
09
08
2019
pubmed:
4
1
2020
medline:
18
11
2020
entrez:
4
1
2020
Statut:
ppublish
Résumé
Bortezomib- and lenalidomide-containing regimens are well-established therapies in multiple myeloma (MM). However, despite their extensive use, head-to-head comparisons have never been performed. Therefore, we compared bortezomib and lenalidomide in fixed-duration therapies. In this open-label, phase III study, we randomized MM patients at first relapse to receive either nine cycles of bortezomib plus cyclophosphamide plus dexamethasone (VCD) or lenalidomide plus cyclophosphamide plus dexamethasone (RCD). The primary endpoint was achievement of a very good partial response (VGPR) or better at six weeks after nine treatment cycles. From March 2011 to February 2015, 155 patients were randomized. VGPR or better was achieved by 12 patients (15%) in the VCD arm and 14 patients (18%) in the RCD arm (P = 0·70). Median progression-free survival (PFS) was 16·3 (95% CI: 12·1-22·4) with VCD and 18·6 months (95% CI: 14·7-25·5) with RCD, and the two-year overall survival (OS) was 75% (95% CI: 66-86%) and 74% (95% CI: 64-85%) respectively. In subgroup analyses, no differences in PFS were observed in bortezomib- and lenalidomide-naïve patients, nor in patients who received a bortezomib-based regimen in first line. Adverse events were consistent with the well-established safety profiles of both drugs. Bortezomib and lenalidomide treatments were equally effective in terms of depth of response, PFS, and OS in MM patients at first relapse.
Substances chimiques
Bortezomib
69G8BD63PP
Dexamethasone
7S5I7G3JQL
Cyclophosphamide
8N3DW7272P
Lenalidomide
F0P408N6V4
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
907-917Subventions
Organisme : Associazione Italiana per la Ricerca sul Cancro
ID : IG-10419
Pays : International
Informations de copyright
© 2019 British Society for Haematology and John Wiley & Sons Ltd.
Références
Attal, M., Harousseau, J.L., Facon, T., Guilhot, F., Doyen, C., Fuzibet, J.G., Monconduit, M., Hulin, C., Caillot, D., Bouabdallah, R., Voillat, L., Sotto, J.J., Grosbois, B., Bataille, R. & the InterGroupe Francophone du Myélome (2003) Single versus double autologous stem-cell transplantation for multiple myeloma. The New England Journal of Medicine, 349, 2495-2502.
Barlogie, B., Anaissie, E., Haessler, J., van Rhee, F., Pineda-Roman, M., Hollmig, K., Alsayed, Y., Epstein, J., Shaughnessy, J.D. & Crowley, J. (2008) Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma. Cancer, 113, 355-359.
Bianchi, G., Richardson, P.G. & Anderson, K.C. (2015) Promising therapies in multiple myeloma. Blood, 126, 300-310.
Biancon, G., Gimondi, S., Vendramin, A., Carniti, C. & Corradini, P. (2018) Noninvasive molecular monitoring in multiple myeloma patients using cell-free tumor DNA: a pilot study. The Journal of Molecular Diagnostics: JMD, 20, 859-870.
Cavo, M., Tacchetti, P., Patriarca, F., Petrucci, M.T., Pantani, L., Galli, M., Di Raimondo, F., Crippa, C., Zamagni, E., Palumbo, A., Offidani, M., Corradini, P., Narni, F., Spadano, A., Pescosta, N., Deliliers, G.L., Ledda, A., Cellini, C., Caravita, T., Tosi, P., Baccarani, M., Italian Myeloma GIMEMA Network (2010) Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet (London, England), 376, 2075-2085.
Dimopoulos, M.A., San-Miguel, J., Belch, A., White, D., Benboubker, L., Cook, G., Leiba, M., Morton, J., Ho, P.J., Kim, K., Takezako, N., Moreau, P., Kaufman, J.L., Sutherland, H.J., Lalancette, M., Magen, H., Iida, S., Kim, J.S., Prince, H.M., Cochrane, T., Oriol, A., Bahlis, N.J., Chari, A., O'Rourke, L., Wu, K., Schecter, J.M., Casneuf, T., Chiu, C., Soong, D., Sasser, A.K., Khokhar, N.Z., Avet-Loiseau, H. & Usmani, S.Z. (2018) Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: Updated analysis of POLLUX. Haematologica, 103, 2088-2096.
Durie, B.G., Jacobson, J., Barlogie, B. & Crowley, J. (2004) Magnitude of response with myeloma frontline therapy does not predict outcome: Importance of time to progression in southwest oncology group chemotherapy trials. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 22, 1857-1863.
Durie, B.G., Harousseau, J.L., Miguel, J.S., Blade, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., Ludwig, H., Gahrton, G., Beksac, M., Crowley, J., Belch, A., Boccadaro, M., Cavo, M., Turesson, I., Joshua, D., Vesole, D., Kyle, R., Alexanian, R., Tricot, G., Attal, M., Merlini, G., Powles, R., Richardson, P., Shimizu, K., Tosi, P., Morgan, G. & Rajkumar, S.V. & International Myeloma Working Group (2006) International uniform response criteria for multiple myeloma. Leukemia, 20, 1467-1473.
Flanders, A., Stetler-Stevenson, M. & Landgren, O. (2013) Minimal residual disease testing in multiple myeloma by flow cytometry: major heterogeneity. Blood, 122, 1088-1089.
Kumar, S.K., Lacy, M.Q., Hayman, S.R., Stewart, K., Buadi, F.K., Allred, J., Laumann, K., Greipp, P.R., Lust, J.A., Gertz, M.A., Zeldenrust, S.R., Bergsagel, P.L., Reeder, C.B., Witzig, T.E., Fonseca, R., Russell, S.J., Mikhael, J.R., Dingli, D., Rajkumar, S.V. & Dispenzieri, A. (2011) Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: Results from a phase 2 trial. American Journal of Hematology, 86, 640-645.
Kyle, R.A. & Rajkumar, S.V. (2008) Multiple myeloma. Blood, 111, 2962-2972.
Lahuerta, J.J., Paiva, B., Vidriales, M.B., Cordón, L., Cedena, M.T., Puig, N., Martinez-Lopez, J., Rosiñol, L., Gutierrez, N.C., Martín-Ramos, M.L., Oriol, A., Teruel, A.I., Echeveste, M.A., de Paz, R., de Arriba, F., Hernandez, M.T., Palomera, L., Martinez, R., Martin, A., Alegre, A., De la Rubia, J., Orfao, A., Mateos, M.V., Blade, J., San-Miguel, J.F. & the GEM (Grupo Español de Mieloma)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas), Cooperative Study Group (2017) Depth of response in multiple myeloma: a pooled analysis of three PETHEMA/GEM clinical trials. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 35, 2900-2910.
Larocca, A. & Palumbo, A. (2016) Optimizing treatment for elderly patients with newly diagnosed multiple myeloma: a personalized approach. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 34, 3600-3604.
Lokhorst, H.M., Plesner, T., Laubach, J.P., Nahi, H., Gimsing, P., Hansson, M., Minnema, M.C., Lassen, U., Krejcik, J., Palumbo, A., van de Donk, N.W., Ahmadi, T., Khan, I., Uhlar, C.M., Wang, J., Sasser, A.K., Losic, N., Lisby, S., Basse, L., Brun, N. & Richardson, P.G. (2015) Targeting CD38 with daratumumab monotherapy in multiple myeloma. The New England Journal of Medicine, 373, 1207-1219.
Lonial, S. & Anderson, K.C. (2014) Association of response endpoints with survival outcomes in multiple myeloma. Leukemia, 28, 258-268.
Lonial, S., Dimopoulos, M., Palumbo, A., White, D., Grosicki, S., Spicka, I., Walter-Croneck, A., Moreau, P., Mateos, M.V., Magen, H., Belch, A., Reece, D., Beksac, M., Spencer, A., Oakervee, H., Orlowski, R.Z., Taniwaki, M., Rollig, C., Einsele, H., Wu, K.L., Singhal, A., San-Miguel, J., Matsumoto, M., Katz, J., Bleickardt, E., Poulart, V., Anderson, K.C., Richardson, P. & ELOQUENT-2 Investigators (2015) Elotuzumab therapy for relapsed or refractory multiple myeloma. The New England Journal of Medicine, 373, 621-631.
McCarthy, P.L., Holstein, S.A., Petrucci, M.T., Richardson, P.G., Hulin, C., Tosi, P., Bringhen, S., Musto, P., Anderson, K.C., Caillot, D., Gay, F., Moreau, P., Marit, G., Jung, S.H., Yu, Z., Winograd, B., Knight, R.D., Palumbo, A. & Attal, M. (2017) Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 35, 3279-3289.
Montefusco, V., Galli, M., Spina, F., Stefanoni, P., Mussetti, A., Perrone, G., De Philippis, C., Dalto, S., Maura, F., Bonini, C., Rezzonico, F., Pennisi, M., Roncari, L., Soldarini, M., Dodero, A., Farina, L., Cocito, F., Caprioli, C. & Corradini, P. (2014) Autoimmune diseases during treatment with immunomodulatory drugs in multiple myeloma: Selective occurrence after lenalidomide. Leukemia & Lymphoma, 55, 2032-2037.
Moreau, P., Masszi, T., Grzasko, N., Bahlis, N.J., Hansson, M., Pour, L., Sandhu, I., Ganly, P., Baker, B.W., Jackson, S.R., Stoppa, A.M., Simpson, D.R., Gimsing, P., Palumbo, A., Garderet, L., Cavo, M., Kumar, S., Touzeau, C., Buadi, F.K., Laubach, J.P., Berg, D.T., Lin, J., Di Bacco, A., Hui, A.M., van de Velde, H., Richardson, P.G. & TOURMALINE-MM1 Study Group (2016) Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. The New England Journal of Medicine, 374, 1621-1634.
Palumbo, A., Gay, F., Cavallo, F., Di Raimondo, F., Larocca, A., Hardan, I., Nagler, A., Petrucci, M.T., Hajek, R., Pezzatti, S., Delforge, M., Patriarca, F., Donato, F., Cerrato, C., Nozzoli, C., Yu, Z., Boccadifuoco, L., Caravita, T., Benevolo, G., Guglielmelli, T., Vincelli, D., Jacques, C., Dimopoulos, M.A., Ciccone, G., Musto, P., Corradini, P., Cavo, M. & Boccadoro, M. (2015) Continuous therapy versus fixed duration of therapy in patients with newly diagnosed multiple myeloma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 33, 3459-3466.
Petrucci, M.T., Giraldo, P., Corradini, P., Teixeira, A., Dimopoulos, M.A., Blau, I.W., Drach, J., Angermund, R., Allietta, N., Broer, E., Mitchell, V. & Blade, J. (2013) A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma. British Journal of Haematology, 160, 649-659.
Quach, H., Ritchie, D., Stewart, A.K., Neeson, P., Harrison, S., Smyth, M.J. & Prince, H.M. (2010) Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia, 24, 22-32.
Rawstron, A.C., Orfao, A., Beksac, M., Bezdickova, L., Brooimans, R.A., Bumbea, H., Dalva, K., Fuhler, G., Gratama, J., Hose, D., Kovarova, L., Lioznov, M., Mateo, G., Morilla, R., Mylin, A.K., Omede, P., Pellat-Deceunynck, C., Perez Andres, M., Petrucci, M., Ruggeri, M., Rymkiewicz, G., Schmitz, A., Schreder, M., Seynaeve, C., Spacek, M., de Tute, R.M., Van Valckenborgh, E., Weston-Bell, N., Owen, R.G., San Miguel, J.F., Sonneveld, P., Johnsen, H.E. & Network, European Myeloma (2008) Report of the european myeloma network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica, 93, 431-438.
Reeder, C.B., Reece, D.E., Kukreti, V., Chen, C., Trudel, S., Hentz, J., Noble, B., Pirooz, N.A., Spong, J.E., Piza, J.G., Zepeda, V.H., Mikhael, J.R., Leis, J.F., Bergsagel, P.L., Fonseca, R. & Stewart, A.K. (2009) Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: High response rates in a phase II clinical trial. Leukemia, 23, 1337-1341.
Spencer, A., Lentzsch, S., Weisel, K., Avet-Loiseau, H., Mark, T.M., Spicka, I., Masszi, T., Lauri, B., Levin, M.D., Bosi, A., Hungria, V., Cavo, M., Lee, J.J., Nooka, A.K., Quach, H., Lee, C., Barreto, W., Corradini, P., Min, C.K., Scott, E.C., Chanan-Khan, A.A., Horvath, N., Capra, M., Beksac, M., Ovilla, R., Jo, J.C., Shin, H.J., Sonneveld, P., Soong, D., Casneuf, T., Chiu, C., Amin, H., Qi, M., Thiyagarajah, P., Sasser, A.K., Schecter, J.M. & Mateos, M.V. (2018) Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: Updated analysis of CASTOR. Haematologica, 103, 2079-2087.
Stewart, A.K., Rajkumar, S.V., Dimopoulos, M.A., Masszi, T., Spicka, I., Oriol, A., Hajek, R., Rosinol, L., Siegel, D.S., Mihaylov, G.G., Goranova-Marinova, V., Rajnics, P., Suvorov, A., Niesvizky, R., Jakubowiak, A.J., San-Miguel, J.F., Ludwig, H., Wang, M., Maisnar, V., Minarik, J., Bensinger, W.I., Mateos, M.V., Ben-Yehuda, D., Kukreti, V., Zojwalla, N., Tonda, M.E., Yang, X., Xing, B., Moreau, P., Palumbo, A. & Investigators, A.S.P.I.R.E. (2015) Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. The New England Journal of Medicine, 372, 142-152.
de Waal, E.G., de Munck, L., Hoogendoorn, M., Woolthuis, G., van der Velden, A., Tromp, Y., Vellenga, E. & Hovenga, S. (2015) Combination therapy with bortezomib, continuous low-dose cyclophosphamide and dexamethasone followed by one year of maintenance treatment for relapsed multiple myeloma patients. British Journal of Haematology, 171, 720-725.
Yee, A.J. & Raje, N.S. (2016) Sequencing of nontransplant treatments in multiple myeloma patients with active disease. American Society of Hematology. Education Program, 2016, 495-503.